Associate Clinical Professor of Psychiatry, Columbia University and New York State Psychiatric Institute, New York, USA.
Robert Wilbur Associates, 125 West 96th Street, Suite 6K, New York, NY 10025, USA.
Ther Adv Psychopharmacol. 2014 Apr;4(2):100-2. doi: 10.1177/2045125314525433.
This clinical study reports upon the efficacy of gabapentin (Neurontin) for treating severe akathisia (3 on the Barnes Akathisia Rating Scale) in two patients receiving quetiapine (Seroquel), one of whom also received olanzapine (Zyprexa) for a short period. The first patient participated in an open-label experiment in which the bedtime dose of gabapentin was discontinued three times at intervals 1 week apart, resulting in severe akathisia which was quickly terminated by taking his usual 1200 mg gabapentin dose. This patient was also taking high doses of two benzodiazepines and a beta blocker, without therapeutic effect upon his akathisia; only gabapentin was efficacious. The second case is a report of a woman taking a high dose of quetiapine for anxiety who experienced severe akathisia which was relieved by taking 1200 mg of gabapentin. Possible mechanisms of action of gabapentin are discussed. Particular attention is drawn to the difference between neuroleptic-induced akathisia and the neurological condition of restless legs syndrome.
本临床研究报告了加巴喷丁（Neurontin）治疗两名接受喹硫平（Seroquel）治疗的患者严重静坐不能（Barnes 静坐不能评定量表 3 级）的疗效，其中一名患者还短期接受了奥氮平（Zyprexa）治疗。第一例患者参加了一项开放性试验，其中三次在间隔一周的时间内停用加巴喷丁的睡前剂量，导致严重的静坐不能，服用常规的 1200 毫克加巴喷丁剂量后很快终止。该患者还同时服用了两种苯二氮䓬类药物和一种β受体阻滞剂，但对其静坐不能没有治疗作用；只有加巴喷丁有效。第二例是一名女性因焦虑服用高剂量喹硫平后出现严重静坐不能，服用 1200 毫克加巴喷丁后缓解的报告。讨论了加巴喷丁作用机制的可能性。特别注意到抗精神病药引起的静坐不能和不宁腿综合征的神经状况之间的区别。
